Table 3.
Functional Outcomes | |||||
---|---|---|---|---|---|
Study | SRS | SS | p–Value | ||
Immediate | Schuetz et al. [20] | 3/21 (14%) | 0/7 (0%) | ||
Madi et al. [19] | 4/16 (25%) | 0/10 (0%) | |||
Kowalczyk et al. [21] | |||||
Total | 7/37 (19%) | 0/17 (0%) | |||
Continence | 12-month | Schuetz et al. [20] | 4/21 (19%) | 0/7 (0%) | 0.0384 |
Madi et al. [19] | 8/8 (100%) | 4/9 (44%) | |||
Kowalczyk et al. [21] | |||||
Total | 12/29 (41%) | 4/16 (25%) | |||
At longest follow up | Schuetz et al. [20] | 4/21 (19%) | 0/7 (0%) | ||
Madi et al. [19] | 8/8 (100%) | 4/9 (44%) | 0.0016 | ||
Kowalczyk et al. [21] | 29/40 (73%) | 14/32 (44%) | |||
Total | 41/69 (59%) | 18/48 (38%) | |||
Potency | Schuetz et al. [20] | ||||
Madi et al. [19] | |||||
Kowalczyk et al. [21] | 4/40 (10%) | 4/32 (12.5%) | 0.886 |